



Date:14/08/2015

To

BSE Limited
Listing Department
P.J.Towers,Dalal Street,
Mumbai – 400001

BSE - Scripe Code : 532660

National Stock Exchange of India Ltd
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra(E),Mumbai – 400051

NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg

The Board of Directors of the Company at its meeting held on August 14, 2015, inter alia, have approved/resolved/taken note of the following:

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchange, considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter ended June 30,2015 attached herewith;
2. The Board took note of Auditor's Limited Review Report on the un Audited Financial Statements of the Company for the quarter ended June 30,2015
3. Appointment of Mr Amarjit Singh Bhatia , as the Chief Financial Officer of the Company effective August 14 , 2015

"Brief about Mr Amarjit Singh Bhatia :

Mr Bhatia has more than two decades of experience in the area of Corporate Finance and has served as a CFO for more than 7 years across his last three assignments.

Mr Bhatia has multi-industry experience in the areas of Private Equity, Structured Finance, Debt funding, Taxation, Project monitoring, Business Planning and Strategy. His last assignment was as CFO for Polygenta Technologies Ltd., a Waste to Textile Company.

Prior to this assignment, he was the CFO for various well known companies , where he was instrumental in raising long term & short term capital and was responsible for the business planning and budgeting of the Company.



Vivimed

At prior points of his professional career he has also been associated with the UPL Group as the CFO for their group Company looking after the whole gamut of finance for the Holding Company and its 17 SPVs.

Mr Bhatia is a qualified Chartered Accountant from ICAI, India


4. Directors Report for the financial year ended 31/03/2015 together with annexure thereto
5. Convening of Annual General Meeting(AGM) 30/09/2015 and Notice of AGM.
6. Fixed Book closure dates from September 26, 2015 to ,September 30, 2015 (both days inclusive) for the purpose of AGM.

An earnings related presentation including business highlights will be uploaded on the company's website www.vivimedlabs.com

You are requested to take note of the above.

Yours faithfully

For **VIVIMED LABS LTD**


SANTOSH VARALWAR
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED
CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED JUNE 30TH 2015

in Lacs

Sl. No.	Particulars	Quarter Ended			Year Ended
		30.06.2015 (Un audited)	31.03.2015 (Audited)	30.06.2014 (Un audited)	31.03.2015 (Audited)
1	Income From Operations				
	(a) Net Sales / Income from Operations (Net of	33,152.85	35,621.52	36,653.65	1,38,009.91
	(b) Other Operating Income	143.60	49.75	122.48	586.57
	Total Income From Operations (Net)	33,296.44	35,671.27	36,776.13	1,38,596.49
	a. Cost of Raw Materials Consumed	15,372.70	17,159.03	18,761.49	69,931.61
	b. Purchase of Stock in Trade	-	-	-	-
	c. Changes in Inventories of finished Inventories of	(553.92)	(425.78)	(1,449.32)	(5,309.20)
	d. Employee Benefit Expenses	4,543.03	4,721.12	4,716.39	18,442.79
	e. Depreciation and Amortisation Expenses	1,478.38	1,470.70	1,650.15	6,617.76
	f. Other Expenditure	7,212.42	8,954.15	8,940.72	33,256.12
2	Total Expenses	28,052.61	31,879.21	32,619.43	1,22,939.08
3	Profit / (Loss) from Operations before Other	5,243.83	3,792.06	4,156.70	15,657.41
4	Other Income	-	-	-	-
5	Profit / (Loss) from Ordinary Activities before	5,243.83	3,792.06	4,156.70	15,657.41
6	Finance Costs	1,904.50	2,157.28	1,840.42	7,903.68
7	Profit / (Loss) from Ordinary Activities after	3,339.33	1,634.78	2,316.28	7,753.73
8	Exceptional Items	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (3,339.33	1,634.78	2,316.28	7,753.73
10	Tax Expenses	921.98	(160.04)	603.24	548.69
11	Net Profit / Loss from ordinary activities after	2,417.35	1,794.82	1,713.05	7,205.04
12	Extraordinary Items (net of tax expenses)	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	2,417.35	1,794.82	1,713.05	7,205.04
14	Share of Profit / (Loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and	2,417.35	1,794.82	1,713.05	7,205.04
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year				
19	Earnings per Share (before Extraordinary Items) (of Rs...../- each) (not annualised)				
	(a) Basic	14.92	11.08	10.57	44.47
	(b) Diluted	14.92	11.08	10.57	44.47

- The above Consolidated Unaudited Financial Results for the quarter ended JUNE'30TH 2015 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 14Th AUGUST'2015
- Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sehen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Labs (Alathur) pvt Limited (vi) Finoso Pharma pvt Limited and its step down subsidiaries viz. (vii) Vivimed Holdings Limited and its stepdown subsidiary Vivimed Labs Europe Limited (viii) Vivimed Labs Mauritius Limited and its stepdown subsidiaries (i) Vivimed Labs UK Limited, (ii) Vivimed Labs Spain, S.L. (iii) Union Quimico Farmaceutica S.A.U., Spain,
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.
- The company has calculated depreciation as per the provisions under companies act of 2013.



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO

Place : Hyderabad
Date : 14.08.2015

VIVIMED LABS LIMITED

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING

In Lacs

Particulars	3 Months Ended			FY 15
	30.06.2015 (Unaudited)	31.03.2015 (Audited)	30.06.2014 (Unaudited)	
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)				
a. Speciality Chemicals Business	9,575.42	14,966.54	8,861.66	44,620.88
b. Pharma Business	23,577.43	20,654.98	27,791.99	93,389.04
Total	33,152.85	35,621.52	36,653.65	1,38,009.92
Less, Inter Segment Revenue				
Net sales / Income from Operations	33,152.85	35,621.52	36,653.65	1,38,009.92
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment				
a. Speciality Chemicals Business	1,740.39	2,186.23	1,787.48	9,004.64
b. Pharma Business	3,503.44	1,605.83	2,369.22	6,652.77
Total	5,243.83	3,792.06	4,156.70	15,657.41
Less: 1. Interest	1,904.50	2,157.28	1,840.42	7,903.68
2. Other Un-allocable Expenditure				
3. Un-allocable Income				
Total Profit Before Tax	3,339.33	1,634.78	2,316.28	7,753.73
3. Capital Employed				
a. Speciality Chemicals Business	81,173.74	80,489.58	81,593.43	80,489.58
b. Pharma Business	68,788.00	68,208.23	65,258.58	68,208.23
Total	1,49,961.74	1,48,697.80	1,46,852.01	1,48,697.80

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)

MANAGING DIRECTOR & CEO



Place : Hyderabad

Date : 14.08.2015

VIVIMED LABS LIMITED
STANDALONE FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED JUNE 30'TH 2015

in Lacs

Sl. No.	Particulars	Quarter Ended			Year ended
		30.06.2015	31.03.2015	30.06.2014	31.03.2015
		(Un audited)	(Audited)	(Un audited)	(Audited)
1	Income From Operations				
	(a) Net Sales / Income from Operations (Net of Excise	7,971.31	12,641.27	10,272.84	43,014.81
	(b) Other Operating Income	12.70	46.72	(1.90)	143.40
	Total Income From Operations (Net)	7,984.01	12,687.99	10,270.94	43,158.21
	a. Cost of Raw Materials Consumed	3,455.20	5,848.41	6,871.71	25,110.30
	b. Purchase of Stock in Trade	-	-	-	-
	c. Changes in Inventories of finished Inventories of	(12.89)	198.75	(1,866.67)	(5,319.45)
	d. Employee Benefit Expenses	529.77	784.72	549.58	2,788.34
	e. Depreciation and Amortisation Expenses	484.51	492.55	448.16	2,056.04
	f. Other Expenditure	1,752.94	3,088.61	2,180.26	9,863.94
2	Total Expenses	6,209.53	10,413.04	8,183.03	34,499.17
3	Profit / (Loss) from Operations before Other Income,	1,774.47	2,274.95	2,087.91	8,659.04
4	Other Income				
5	Profit / (Loss) from Ordinary Activities before Finance	1,774.47	2,274.95	2,087.91	8,659.04
6	Finance Costs	1,492.82	1,599.98	1,427.60	6,233.53
7	Profit / (Loss) from Ordinary Activities after Finance	281.65	674.97	660.31	2,425.51
8	Exceptional items				
9	Profit / Loss from ordinary activities before Tax (7 -	281.65	674.97	660.31	2,425.51
10	Tax Expenses	64.86	115.20	177.17	531.99
11	Net Profit / Loss from ordinary activities after Tax (216.79	559.77	483.14	1,893.52
12	Extraordinary Items (net of tax expenses Rs.....Lacs)				
13	Net Profit / Loss for period (11 - 12)	216.79	559.77	483.14	1,893.52
14	Share of Profit / (Loss) of associates				
15	Minority Interest				
16	Net Profit / Loss after taxes, Minority Interest and	216.79	559.77	483.14	1,893.52
17	Paid up Equity Share Capital (Face value of the Share sha	1,620.38	1,620.38	1,620.38	1,620.38
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year				
19	Earnings per Share (before Extraordinary Items) (of Rs...../- each) (not or				
	(a) Basic	1.34	3.45	2.98	11.69
	(b) Diluted	1.34	3.45	2.98	11.69

- The above Standalone Unaudited Financial Results for the Quarter ended JUNE'30'TH 2015 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 14' th AUGUST '2015
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.
- The company has calculated depreciation as per the provisions under companies act of 2013.



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO

Place : Hyderabad
Date : 14.08.2015

VIVIMED LABS LIMITED
SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT

in Lacs

Particulars	3 Months Ended			FY 15 31-03-2015 (Audited)
	30.06.2015 (Unaudited)	31.03.2015 (Audited)	30.06.2014 (Unaudited)	
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)				
a. Speciality Chemicals Business	6,066.04	10,866.81	7,999.69	34,941.15
b. Pharma Business	1,905.28	1,774.46	2,273.15	8,073.66
Total	7,971.31	12,641.27	10,272.84	43,014.81
Less, Inter Segment Revenue				
Net sales / Income from Operations	7,971.31	12,641.27	10,272.84	43,014.81
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment				
a. Speciality Chemicals Business	1,636.90	2,000.46	1,560.40	7,271.32
b. Pharma Business	137.57	274.49	527.51	1,387.72
Total	1,774.47	2,274.95	2,087.91	8,659.04
Less: 1. Interest	1,492.82	1,599.98	1,427.60	6,233.53
2. Other Un-allocable Expenditure				
3. Un-allocable Income				
Total Profit Before Tax	281.65	674.97	660.31	2,425.51
3. Capital Employed				
a. Speciality Chemicals Business	81,955.60	81,345.51	80,178.40	81,345.51
b. Pharma Business	31,968.95	31,889.23	27,036.96	31,889.23
Total	1,13,924.55	1,13,234.74	1,07,215.36	1,13,234.74

Place : Hyderabad
 Date : 14.08.2015



For VIVIMED LABS LIMITED,
 (SANTOSH VARALWAR)
 MANAGING DIRECTOR & CEO

Part II					
Select Information for the Quarter Ended 30/06/2015					
Sl.No	Particulars	Quarter ended 30/06/2015	Quarter ended 31/03/2015	Quarter ended 30/06/2014	Year ended 31/03/2015
A	PARTICULARS OF SHAREHOLDING				
	Public Shareholding				
	Number of Shares	10210555	10059058	10026058	10059058
	Percentage of Shareholding	63.01%	62.08%	61.87%	62.08%
	Promoter and Promoter Group Shareholding				
	(a) Pledged/ Encumbered				
	Number of Shares	4998000	4823000	2750455	4823000
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	83.39%	78.49%	44.52%	78.49%
	Percentage of shares (as a % of the total share capital of the company)	30.85%	29.76%	16.98%	29.76%
	(b) Non-encumbered				
	Number of Shares	995228	1321725	3427270	1321725
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	16.61%	21.51%	55.48%	21.51%
	Percentage of shares (as a % of the total share capital of the company)	6.14%	8.16%	21.15%	8.16%

Investor's Complaints

Sl.no	Particulars	3 months ended 30/06/2015
B	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

To
The Board of Directors
VIVIMED LABS LIMITED
Hyderabad

Limited Review Report for the quarter ended 30th June , 2015

1. We have reviewed the accompanying statement of unaudited financial results of M/s. **VIVIMED LABS LIMITED** for the quarter ended 30th June, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants



Partner

Place: Hyderabad
Date: 14th August 2015